SCHEMBL16253429

SCHEMBL16253429

[2H]C([2H])([2H])C([2H])([2H])n1ncc2cc(Nc3nc(NC4CCCN(C)C4)nnc3C(N)=O)ccc21

nearest known ligand 0.62

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 11/20 0.62
▸ EGFR P00533 5/20 0.47
▸ LCK P06239 5/20 0.47
▸ JAK3 P52333 4/20 0.47
▸ BTK Q06187 6/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16253428 0.87 SYK (0.63) SYK
SCHEMBL15910711 0.87 SYK (0.83) SYKEGFRLCKJAK3BTK
SCHEMBL16253424 0.86 SYK (0.68) SYKBTK
SCHEMBL16253423 0.85 SYK (0.75) SYKBTK
SCHEMBL16253425 0.85 SYK (0.75) SYKBTK
SCHEMBL15910587 0.84 SYK (0.82) SYK
SCHEMBL16253427 0.84 SYK (0.82) SYK
SCHEMBL15910736 0.83 SYK (0.68) SYK
SCHEMBL23081034 0.82 SYK (0.73) SYKEGFRLCKJAK3BTK
SCHEMBL16253430 0.82 SYK (0.54) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9145414-B2 1,2,4-triazine-6-carboxamide derivative TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-09-29 — — US disclosed
US-20140343038-A1 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE TAIHO PHARMACEUTICAL CO., LTD. (JP) 2014-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343038-A1 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE SYK, BTK, JAK2 SYK 1/4885EGFR 86/4885LCK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback